Book a Meeting During ISPOR Annual 2025 and be Entered to Win a Ninebot Segway Electric Scooter

Booth #821 | May 13 - 16, 2025

Schedule Now

Home / Book a Meeting During ISPOR Annual 2025 and be Entered to Win a Ninebot Segway Electric Scooter

Connect with us to explore the topics that matter:

  • Cross-functional integration of HEOR evidence generation and value communication strategies
    • Integrated value proposition development early in the commercialization process
    • Overcoming silos (Medical Affairs, Market Access, Commercial) to maximize holistic value props and drive pre-/peri-launch evidence goals
    • Identification of key evidence needs, taking a multi-stakeholder lens
    • Justifying and demonstrating ROI in evidence generation and value comms
  • Global HTA, pricing and access priorities
    • Strategies for success in the EU amid rising access barriers and increasing payer cost-management pressures
    • JCA and its implications for launch planning, standard procedures and timelines
    • The next wave of high-impact markets for brand success beyond U.S., EU and Japan
  • Innovation in value strategy
    • Enhancement of value proposition development for new/first launch therapies to maximize value and address HTA/Payer priorities
    • An integrated document that consolidates all your patient experience data into one comprehensive file, serving as a single point of truth for the regulatory and HTA dossiers
    • Customized approaches to communicate value, designed for specific stakeholder types
  • Best practices in conducting evidence-grade RWE studies
    • Working with RWD/Claims, Medical Chart Audit, Burden of Illness and HCP/Patient Preference in the U.S., EU and key global markets
    • Handling paperwork and timeliness associated with central IRBs, Center-Specific and Ethics Committee Reviews
    • Effectively recruiting participants (HCPs, Patients and Caregivers) in different markets while being compliant to country and site requirements
  • Focus on real-world data sources (U.S./ex-U.S.), using both primary and secondary research options
    • Best practices in pragmatic, compelling research
    • Impactful evidence generation in key global markets